The great thing is that the FDA sees potential in PBT2. I think efficacy for both HD and AD will be improved at higher doses. HD patients have few alternatives and the early results showed promise it will be interesting to see if there is an off label mkt for PBT2 for AD if it is approved. The Imagine extension trial continues and may yet provide some great longitudinal data.
GLTA
The mouse may roar again
The great thing is that the FDA sees potential in PBT2. I think...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $114.9K | 38.30M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 107704923 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 25649026 | 2 |
View Market Depth
| Last trade - 15.57pm 16/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |